ホームページ ER stress & UPR -Immunology & Inflammation PKR

PKR

PKR製品

  • All (5)
  • PKR阻害剤 (1)
  • PKR活性剤(1)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S9668 PKR-IN-C16 PKR-IN-C16 (C16, Imidazolo-oxindole PKR inhibitor C16) is a specific inhibitor of RNA-dependent protein kinase (PKR, Protein Kinase R, EIF2AK2). PKR-IN-C16 prevents apoptosis and IL-1β production in an acute excitotoxic rat model with a neuroinflammatory component.
Immunity, 2025, 58(10):2489-2504.e8
Exp Mol Med, 2024, 56(2):408-421.
EMBO J, 2024, 43(5):780-805.
F1207 PKR Antibody [K23G2] PKR Rabbit mAb recognizes endogenous levels of total PKR protein.
F1597 Phospho-PKR (Thr446) Antibody [K16N13]
F2996New PACT (PKR activating protein) / PRKRA Antibody [F4M5]
E2388 PKR-IN-2 PKR-IN-2 is a pyruvate kinase isoform PKR activator extracted from patent WO2014139144A1, compound 160, which can be used for the research of PKR function related diseases, including cancer, diabetes, obesity, autoimmune disorders, and benign prostatic hyperplasia.
S9668 PKR-IN-C16 PKR-IN-C16 (C16, Imidazolo-oxindole PKR inhibitor C16) is a specific inhibitor of RNA-dependent protein kinase (PKR, Protein Kinase R, EIF2AK2). PKR-IN-C16 prevents apoptosis and IL-1β production in an acute excitotoxic rat model with a neuroinflammatory component.
Immunity, 2025, 58(10):2489-2504.e8
Exp Mol Med, 2024, 56(2):408-421.
EMBO J, 2024, 43(5):780-805.
E2388 PKR-IN-2 PKR-IN-2 is a pyruvate kinase isoform PKR activator extracted from patent WO2014139144A1, compound 160, which can be used for the research of PKR function related diseases, including cancer, diabetes, obesity, autoimmune disorders, and benign prostatic hyperplasia.
F2996New PACT (PKR activating protein) / PRKRA Antibody [F4M5]
united states